GlobeNewswire

2024-12-05 11:58

Cambium Bio Successfully Closes A$3.0M Financing Round

SYDNEY, Dec. 05, 2024 (GLOBE NEWSWIRE) --  Cambium Bio Limited (ASX:CMB) (Cambium Bio, Cambium or Company), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the successful completion of a A$3.0 million capital raising.

Key Highlights:

  • Capital raising of A$3.0 million completed at A$0.4637 per share, representing a 25% discount to the 5-day Volume Weighted Average Price (VWAP) up to and including 2 December 2024
  • Strong support from new strategic investor AventaCell Biomedical Corp and existing major shareholder Zheng Yang Biomedical Technology
  • Additional participation from Cambium Bio directors, CEO, and Australian institutional and sophisticated investors
  • Proceeds to advance Phase 3 clinical development of Elate Ocular® for dry eye disease

The capital raising, which was approved by shareholders at the Annual General Meeting held on 26 November 2024, comprises:

  • A$1.5 million strategic investment from AventaCell Biomedical Corp
  • A$0.25 million investment from Zheng Yang Biomedical Technology
  • A$0.146 million from Cambium Bio directors
  • A$1.054 million from Cambium Bio CEO, Australian institutional, sophisticated and other investors

Cambium Bio CEO, Karolis Rosickas, commented: "We are delighted with the strong support received in this capital raising, particularly from AventaCell Biomedical Corp as a new strategic investor. AventaCell's global leadership in cell culture supplements using our human platelet technology makes them an ideal partner as we advance our therapeutic programs. The participation of our existing major shareholder ZYBT, along with directors and management, demonstrates continued confidence in our strategy and clinical and commercial potential of Elate Ocular®."

Use of Funds

The proceeds will primarily support the advancement of Elate Ocular® through its registration-enabling Phase 3 clinical trials for dry eye disease, which are planned to commence in calendar Q2 2025. The funds will also provide working capital for the Company's ongoing operations.

For further information, please contact:
Helen Leung
Corporate Secretary
info@cambium.bio
1 300 995 098


Primary Logo

source: Cambium Bio Limited

【你點睇?】新一份預算案公布,多項開源節流措施推出,你認為哪一項措施最能達致改善政府財赤目標?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
3
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
4
財政預算案2025 | 重點文字直播/Youtube直播(稍後送上懶人包)
5
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
6
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
9
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
10
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
11
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
12
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
13
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
14
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
15
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
16
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
17
高息定存 | 信銀國際12個月港元定存高達3.5厘
18
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
19
民營企業座談會 | 習近平在京出席民營企業座談會
20
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
21
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
22
David Webb:因病情惡化,將有序結束個人財經網站
23
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
24
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
25
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
26
港股 | 蕭猷華:恒指升勢可持續?
27
比特幣 | 亞洲時段虛擬貨幣大幅下跌,31萬人爆倉
28
2025強積金整合獎賞一覽 轉供應商最多竟然可賺!?
29
美股收盤 | 美股三大指數收市報跌,道指跌近750點
30
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

2025-26年度財政預算案

大國博弈

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老